By Professor Gail Matthews

Journal articles

Dore GJ; Hellard M; Matthews G; Haber PS; Shaw D; Yeung B; Petoumenos K; Van Beek IA; Mccaughan GW; Pan Y; Ffrench R; Rowlinson W; Lloyd AR; Kaldor JM, 2007, 'Treatment of recently acquired hepatitis C infection in injecting drug users: Preliminary results from the Australian trial in acute hepatitis C (ATAHC)', Hepatology, 46, pp. 358A - 358A

Matthews G; Bartholomeusz A; Locarnini S; Ayres A; Sasaduesz J; Seaberg E; Cooper DA; Lewin S; Dore GJ; Thio C, 2006, 'Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy', AIDS, 20, pp. 863 - 870

Menon-Johansson AS; Winston A; Matthews G; Portsmouth S; Daniels D, 2005, 'The first point prevalence study of genital Chlamydia trachomatis infection in young male inmates in the UK', International Journal of STD and AIDS, 16, pp. 799 - 801, http://dx.doi.org/10.1258/095646205774988145

Nelson M; Matthews G; Brook MG; Main J; BHIVA Coinfection Guideline Committee ; British HIV Association , 2005, 'BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis C virus infection (2005).', HIV Med, 6 Suppl 2, pp. 96 - 106, http://dx.doi.org/10.1111/j.1468-1293.2005.00300.x

Matthews G; Kronborg I; Dore GJ, 2005, 'Treatment for hepatitis C virus infection among current injection drug users in Australia', Clinical Infectious Diseases, 40, pp. S325 - S329

Matthews G; Dore G, 2003, 'Response to Soriano et al., 'Treatment of chronic hepatitis C virus infection: We must target the virus or liver fibrosis?' [3]', AIDS, 17, pp. 2675 - 2676

Bell C; Matthews GV; Nelson MR, 2003, 'Non-nucleoside reverse transcriptase inhibitors - An overview', International Journal of STD and AIDS, 14, pp. 71 - 77, http://dx.doi.org/10.1258/095646203321156827

Nelson M; Portsmouth S; Stebbing J; Atkins M; Barr A; Matthews G; Pillay D; Fisher M; Bower M; Gazzard B, 2003, 'An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals', AIDS, 17, pp. F7 - F10, http://dx.doi.org/10.1097/00002030-200301030-00002

Nelson MR; Matthews G; Brook MG; Main J; British HIV Association , 2003, 'BHIVA guidelines: coinfection with HIV and chronic hepatitis C virus.', HIV Med, 4 Suppl 1, pp. 52 - 62, http://dx.doi.org/10.1046/j.1468-1293.4.s1.2.x

Matthews G; Dore C, 2003, 'Response to Soriano et al., `Treatment of chronic hepatitis C virusinfection: we must target the virus or liver fibrosis?`', AIDS, 17, pp. I - II

Matthews G; Dore GJ, 2003, 'Treatment of chronic hepatitis c virus infection: we must target the virus or liver fibrosis (letter)?', AIDS, 17, pp. 2675 - 2676

Dean GL; Edwards SG; Ives NJ; Matthews G; Fox EF; Navaratne L; Fisher M; Taylor GP; Miller R; Taylor CB; De Ruiter A; Pozniak AL, 2002, 'Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy', AIDS, 16, pp. 75 - 83, http://dx.doi.org/10.1097/00002030-200201040-00010

Matthews GV; Sabin CA; Mandalia S; Lampe F; Phillips AN; Nelson MR; Bower M; Johnson MA; Gazzard BG, 2002, 'Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: A cohort study', AIDS, 16, pp. 53 - 61, http://dx.doi.org/10.1097/00002030-200201040-00008

Matthews GV; Pillay D; Cane P; Ratcliffe D; Gazzard B; Nelson M, 2001, 'Failure of combination therapy with lamivudine and famciclovir following lamivudine monotherapy for hepatitis B virus infection in patients coinfected with human immunodeficiency virus-1', Clinical Infectious Diseases, 33, pp. 2049 - 2054, http://dx.doi.org/10.1086/322655

Matthews GV; Nelson MR, 2001, 'The management of chronic hepatitis B infection', International Journal of STD and AIDS, 12, pp. 353 - 357, http://dx.doi.org/10.1258/0956462011923273

Matthews G; Worrall S; Daniels D, 2001, 'Provision of sexual health services in young offender institutions: Is there gender inequality? [2]', International Journal of STD and AIDS, 12, pp. 130 - 131

Powles T; Matthews G; Bower M, 2000, 'AIDS related systemic non-Hodgkin's lymphoma', Sexually Transmitted Infections, 76, pp. 335 - 341, http://dx.doi.org/10.1136/sti.76.5.335

Matthews GV; Bower M; Mandalia S; Powles T; Nelson MR; Gazzard BG, 2000, 'Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy', Blood, 96, pp. 2730 - 2734, http://dx.doi.org/10.1182/blood.v96.8.2730

Matthews GV; Bower M; Mandalia S; Powles T; Nelson MR; Gazzard BG, 2000, 'Changes in acquired immunodeficiency syndrome–related lymphoma since the introduction of highly active antiretroviral therapy', Blood, 96, pp. 2730 - 2734, http://dx.doi.org/10.1182/blood.v96.8.2730.h8002730_2730_2734

Matthews GV; Moyle GJ; Mandalia S; Bower M; Nelson M; Gazzard BG, 2000, 'Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy', Journal of Acquired Immune Deficiency Syndromes, 24, pp. 310 - 315, http://dx.doi.org/10.1097/00126334-200008010-00002

Nelson MR; Matthews GV, 2000, 'Newer treatment strategies in the management of HIV/AIDS', CME Bulletin Sexually Transmitted Infections and HIV, 4, pp. 3 - 5

Matthews G; Bower M; Mandalia S; Powles T; Nelson M; Gazzard B, 2000, '012 AIDS‐related lymphoma in the era of HAART', HIV Medicine, 1, pp. 169 - 169, http://dx.doi.org/10.1046/j.1468-1293.2000.00024-23.x

Dean G; Edwards S; Navaratne L; Matthews G; Fox E; Wood C; Fisher M; Churchill D; Taylor G; De Ruiter A; Taylor C; Pozniak A, 2000, '014 Does TB treatment alter virological and immunological response to HAART?', HIV Medicine, 1, pp. 170 - 170, http://dx.doi.org/10.1046/j.1468-1293.2000.00024-27.x

Matthews GV; Moyle GJ; Mandalia S; Bower M; Nelson M; Gazzard BG, 2000, 'Absence of Association Between Individual Thymidine Analogues or Nonnucleoside Analogues and Lipid Abnormalities in HIV-1–Infected Persons on Initial Therapy', Journal of Acquired Immune Deficiency Syndromes, 24, pp. 310 - 315, http://dx.doi.org/10.1097/00042560-200008010-00002

Matthews G; Ratcliffe D; Cane P; Pillay D; Gazzard B; Nelson M, 2000, 'P34 Failure of sequential nucleoside analogue monotherapy for the treatment of HBV in HIV/HBV co‐infected patients', HIV Medicine, 1, pp. 183 - 183, http://dx.doi.org/10.1046/j.1468-1293.2000.00024-115.x

Matthews G; Moyle G; Mandalia S; Bower M; Nelson M; Gazzard B, 2000, 'P35 Is there an association between choice of thymidine analogue and lipid abnormalities in HIV‐1‐infected patients?', HIV Medicine, 1, pp. 183 - 183, http://dx.doi.org/10.1046/j.1468-1293.2000.00024-117.x

Matthews G; Pozniak AL, 1999, 'Opportunistic infections in the era of HAART', Sexually Transmitted Infections, 75, pp. 214 - 217

Matthews G; Gornall R; Saunders NJ, 1997, 'A randomised placebo controlled trial of loop diuretics in moderate/severe pre-eclampsia, following delivery', Journal of Obstetrics and Gynaecology, 17, pp. 30 - 32, http://dx.doi.org/10.1080/01443619750114040

Carney S; Morgan T; Wilson M; Matthews G; Roberts R, 1975, 'Sodium restriction and thiazide diuretics in the treatment of hypertension.', Medical Journal of Australia, 1, pp. 803 - 807, http://dx.doi.org/10.5694/j.1326-5377.1975.tb82051.x

Matthews G; Morgan T, 1973, 'Diuretics and potassium depletion in hypertension', Australian and New Zealand Journal of Medicine, 3, pp. 432

Conference Papers

George J; Stefanova-Petrova D; Antonov K; Valaydon Z; Davison S; Fung S; Chen F; Cooper C; Roberts S; Vachon M-L; Coffin CS; Conway B; Matthews G; Radicheva M; Knox SJ; Yan R; Thi EP; Chan C; Liu J; Zomorodi K; Eley T; Anderson M; Sims K; Stamm LM; Picchio GR; Wang G; Balabanska R; MacQuillan G; Elkhashab M, 2023, 'EVALUATION OF THE VEBICORVIR, NRTI AND AB-729 COMBINATION IN VIROLOGICALLY SUPPRESSED PATIENTS WITH HBEAG NEGATIVE CHRONIC HEPATITIS B VIRUS INFECTION: INTERIM ANALYSIS FROM AN OPEN LABEL PHASE 2 STUDY', in HEPATOLOGY, LIPPINCOTT WILLIAMS & WILKINS, MA, Boston, pp. E169 - E170, presented at American Association for the Study of Liver Diseases (AASLD), MA, Boston, 10 November 2023 - 14 November 2023

MacQuillan G; Elkhashab M; Antonov K; Valaydon Z; Davidson S; Fung SK; Vincent C; Bailey R; Chen F; Cooper C; Roberts S; Vachon M-L; Coffin CS; Matthews G; Radicheva M; Knox SJ; Yan R; Thi EP; Chan C; Liu J; Zomorodi K; Eley T; Stamm LM; Sims K; Anderson M; Picchio G; Wang G; Balabanska R; Tsrancheva R; George J, 2023, 'PRELIMINARY OFF-TREATMENT RESPONSES FOLLOWING 48 WEEKS OF VEBICORVIR, NUCLEOS(T) IDE REVERSE TRANSCRIPTASE INHIBITOR, AND AB-729 COMBINATION IN VIROLOGICALLY SUPPRESSED PATIENTS WITH HEPATITIS B E ANTIGEN NEGATIVE CHRONIC HEPATITIS B: ANALYSIS FROM AN OPEN-LABEL PHASE 2 STUDY', in HEPATOLOGY, LIPPINCOTT WILLIAMS & WILKINS, MA, Boston, pp. S47 - S49, presented at Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 10 November 2023 - 14 November 2023

Harney B; Sacks-Davis R; Agius P; van Santen D; Traeger M; Wilkinson A; Asselin J; El-Hayek C; Fairley C; Roth N; Bloch M; Matthews G; Donovan B; Guy R; Stoove M; Hellard M; Doyle J, 2023, 'Risk of hepatitis C infection following bacterial sexually transmissible infections among gay and bisexual men in Australia 2016-2020', in JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, JOHN WILEY & SONS LTD

Clifford B; Acheson LS; Brener L; Siefried KJ; Steele M; Matthews G; Ezard N, 2022, 'A qualitative exploration of client and healthcare provider perspectives on why people who inject drugs with injecting-related infections discharge against medical advice', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S43 - S44, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000862018700077&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Morphett K; Puljevic C; Boyd M; Bonevski B; Gilks C; Borland R; Courtney R; Mcrobbie H; Baker P; Winston A; Baker AL; Matthews G; Chatfield M; Farrell M; Mattick RP; Ferguson S; Blakely T; Hall WD; Gartner C, 2021, 'A PRAGMATIC RANDOMISED PARTIAL CROSSOVER CLINICAL TRIAL OF NICOTINE VAPORISERS ADDED TO STANDARD CARE FOR SMOKING CESSATION AND RELAPSE PREVENTION AMONG PRIORITY POPULATIONS WITH COMORBIDITIES', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S15 - S15, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000715073200031&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hall S; Burns G; Anagnostou D; Vogrin S; Sundararajan V; Ratnam DT; Levy MT; Lubel JS; Nicoll AJ; Strasser SI; Sievert W; Desmond PV; Ngu MC; Angus PW; Maree S; Meredith C; Matthews G; Revill P; Jackson K; Bonanzinga S; Canchola J; Kuchta A; Torres J; Bowden S; Locarnini S; Visvanathan K; Thompson A, 2021, 'FINAL RESULTS OF THE HBV-STOP STUDY - LOW BASELINE HBsAg LEVELS PREDICT DISEASE REMISSION AND HBsAg LOSS AFTER STOPPING NUCLEOT(S)IDE ANALOGUES IN CHRONIC HEPATITIS B E-ANTIGEN NEGATIVE PATIENTS', in HEPATOLOGY, WILEY, pp. 482A - 483A, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000707188002197&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hall S; Burns G; Anagnostou D; Vogrin S; Sundararajan V; Ratnam D; Levy M; Lubel J; Nicoll A; Strasser S; Sievert W; Desmond P; Ngu M; Angus P; Sinclair M; Meredith C; Matthews G; Revill P; Jackson K; Bowden S; Locarnini S; Visvanathan K; Thompson A, 2021, 'Low baseline HBsAg levels predict disease remission and HBsAg loss after stopping nucleot(s)ide analogs in chronic hepatitis B e-antigen-negative patients: Final results of the HBV-STOP study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 65 - 65, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693377800107&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Cysique LA; Allen-Davidian Y; Darley DR; Byrne A; Wilhelm K; Dore G; Matthews G; Brew BJ, 2021, '032 Cognitive deficits are associated with anosmia but not anxio-depressive symptoms in COVID-19', in BMJ Neurology Open, BMJ, pp. a12 - a12, presented at Oral abstracts, http://dx.doi.org/10.1136/bmjno-2021-anzan.32

Casey J; MacParland S; Zahoor A; Janssen HLA; Matthews G; Marks P; Grebely J; Dore G; Hansen BE; Kaul R; Chua C; Gehring AJ; Feld JJ, 2020, 'RESTORATION OF HCV-SPECIFIC T CELLS FOLLOWING DAA THERAPY IN ACUTE HCV INFECTION-SUPPORT FOR TREATMENT OF ACUTE INFECTION.', in HEPATOLOGY, WILEY, ELECTR NETWORK, pp. 613A - 614A, presented at Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 November 2020 - 16 November 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000574027002142&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Walsh KW; Martinello M; Churkin A; Lou S; Applegate T; Etzion O; Uprichard SL; Cotler SJ; Barash D; Matthews G; Dahari H, 2019, 'MODELING INDICATES 100% NEGATIVE PREDICTIVE VALUE OF ACHIEVING CURE IN SUBJECTS WITH RECENT HCV INFECTION TREATED FOR 6 WEEKS WITH SOFOSBUVIR AND RIBAVIRIN: THE DARE II STUDY', in HEPATOLOGY, WILEY, MA, Boston, pp. 969A - 970A, presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, MA, Boston, 08 November 2019 - 12 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488653503298&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Bradshaw D; Vasylyeva T; Davis C; Pybus O; Theze J; Thomson E; Martinello M; Matthews G; Burholt R; Gilleece Y; Cooke G; Page E; Waters L; Nelson M, 2019, 'Risk factors and patterns of HCV transmission amongst men who have sex with men', in HIV MEDICINE, WILEY, pp. 12 - 12, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000463022600024&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Artenie AA; Cunningham E; Conway B; Dalgard O; Powis J; Bruggmann P; Hellard M; Cooper C; Read P; Feld JJ; Hajarizadeh B; Amin J; Applegate TL; Dillon JF; Fraser C; Gane E; Litwin AH; Marks P; Matthews GV; Quiene S; Thurnheer MC; Weltman M; Dore G; Bruneau J; Grebely J, 2018, 'Drug and alcohol use patterns during and following treatment with sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use: Insights from trajectory analyses', in JOURNAL OF VIRAL HEPATITIS, WILEY, CANADA, Toronto, pp. 31 - 32, presented at 16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD), CANADA, Toronto, 14 June 2018 - 17 June 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000435101000046&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Doyle J; Iser D; Sasadeusz J; Roney J; Cutts J; Bowring A; Winter R; O'reilly M; Fairley C; Gane E; Hoy J; Matthews G; Medland N; Moore R; Prins M; Tee B; Stoove M; Hellard M, 2018, 'Hepatitis C treatment success in primary and tertiary care among people with HCV/HIV coinfection', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, pp. S314 - S314, presented at International Liver Congress (ILC), FRANCE, Paris, 11 April 2018 - 15 April 2018, http://dx.doi.org/10.1016/S0168-8278(18)30846-8

Lamoury F; Hajarizadeh B; Martinello M; Soker A; Martinez D; Cunningham P; Cloherty GA; Marks P; Matthews G; Amin J; Grebely J; Dore G; Applegate TL, 2016, 'Hepatitis C virus core antigen: A simplified treatment monitoring tool among those with recent Hepatitis C virus infection, including for post-treatment relapse', in HEPATOLOGY, WILEY, MA, Boston, pp. 415A - 415A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493802113&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Barr E; Rockstroh JK; Nelson M; Katlama C; Lalezari J; Mallolas J; Bloch M; Matthews G; Saag MS; Zamor P; Orkin C; Gress J; Shaughnessy M; Klopfer S; Howe A; Wahl J; Nguyen BY; Robertson M; Platt HL; Sulkowski M, 2016, 'High efficacy of elbasvir/grazoprevir (EBR/GZR) in HCV genotype 1, 4, and 6-infected patients with HIV coinfection: SVR24 data from the phase 3 C-EDGE Coinfection study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, pp. 66 - 66, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000384664700121&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Rockstroh JK; Nelson M; Katlama C; Lalezari JP; Mallolas J; Bloch M; Matthews G; Saag M; Zamor PJ; Orkin C; Gress J; Shaughnessy M; Klopfer S; Howe AY; Wahl J; Nguyen B-YT; Barr E; Platt HL; Robertson M; Sulkowski MS, 2015, 'High Efficacy of Grazoprevir/Elbasvir (GZR/EBR) in HCV Genotype 1, 4, and 6-infected Patients With HIV Coinfection: SVR24 Data From the Phase 3 C-EDGE Coinfection Study', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, pp. 317A - 317A, presented at 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 13 November 2015 - 17 November 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000368375401095&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Waziry RK; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews G; Law M; Dore G; Law M, 2015, 'Trends in end-stage liver disease among people notified with HBV or HCV in New South Wales, Australia: 2000-2014', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, pp. 1121A - 1121A, presented at 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 13 November 2015 - 17 November 2015

Rockstroh JK; Nelson M; Katlama C; Lalezari J; Mallolas J; Bloch M; Matthews G; Saag MS; Zamor P; Orkin C; Gress J; Shaughnessy M; Klopfer S; Platt HL; Robertson M; Sulkowski M, 2015, 'High efficacy of grazoprevir/elbasvir in HCV genotype 1, 4 and 6-infected patients with HIV co-infection: the phase 3 C-EDGE co-infection study', in JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, JOHN WILEY & SONS LTD, http://dx.doi.org/10.7448/IAS.18.5.20545

Durier N; Ruxrungtham K; Avihingsanon A; Kinh NV; Bui VH; Yunihastuti E; Sulaiman AS; Omar SFBS; Yee IA; Morgan P; Boettiger D; Matthews G, 2014, 'Hepatitis C virus RNA and genotype, IL28B genotype, and liver fibrosis scores in a regional cohort of HIV-HCV co-infected patients under routine HIV care in Asia', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 941A - 941A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014

Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV, 2014, 'Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: The ATAHC II and DARE-C i studies', in Antiviral Therapy, SAGE Publications, MA, Boston, pp. 425 - 434, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014, http://dx.doi.org/10.3851/IMP3035

Back to profile page